Quest, Labcorp Tout Their Alzheimer’s Tests and Use of AI

By Mark Terry | From the Volume XXXII, No. 17 – December 8, 2025 Issue

Executives at Quest Diagnostics and Labcorp cheered strong revenue growth in the third quarter. Both companies noted excellent recent launches of Alzheimer’s disease tests. In addition, both companies reported they are leaning heavily into artificial intelligen…

Read More

---

News Briefs on Alzheimer’s Detection

By Scott Wallask | From the Volume XXXII, No. 9 – June 23, 2025 Issue

FDA-cleared IVD could replace scans There has been a significant amount of activity in recent weeks as it concerns tests to detect Alzheimer’s disease. Clinical labs and neuropathologists will want to keep a cl…

Read More

---

Quest, Labcorp CEOs Discuss Tariff Strategies with Investors

By Robert Michel | From the Volume XXXII, No. 7 – May 12, 2025 Issue

Leaders at Labcorp and Quest Diagnostics indicated that they are prepared to weather at least the early months of the unfolding tariff war that is upending the global economy. “There will be some impact from …

Read More

---

Insights from Q3 2024 Earnings Calls Point to a More Robust Lab Market

By Robert Michel | From the Volume XXXI No. 15 – November 4, 2024 Issue

FOR THE THIRD QUARTER OF 2024 (Q3 2024), both of the nation’s largest publicly traded laboratories—Labcorp…

Read More

---

Q3 2023 Financial Reports Show Growth at Labcorp, Quest

By Robert Michel | From the Volume XXX, Number 16 – November 13, 2023 Issue

Blood brothers Labcorp and Quest Diagnostics showed momentum beyond COVID-19 testing and toward areas that grew base business revenue in their third quarter (Q3) 2023 financial reporting. Company leaders called attention to more partnerships and acquisitions of ho…

Read More

---